Skip to main content
. 2024 Jan 2;15:186. doi: 10.1038/s41467-023-44559-3

Fig. 2. ApoL6 inhibits lipolysis.

Fig. 2

a Differentiated 3T3-L1 adipocytes were infected with inducible lentiviral ApoL6. Induction was achieved by treating the cells with Dox for 3 h before experiment. No Dox-treatment was used as control. FFA and glycerol release in the media from cells in basal and isoproterenol-stimulated conditions was measured. FFA (n = 5, *p = 0.016, **p = 0.0039, multiple t test), glycerol (n = 5, *p = 0.043, **p = 0.0055, multiple t test). Data represent mean ± SD. Independent experiment were repeat twice. b FFA release from human adipocytes after infection with lentiviral h-ApoL6-HA (n = 3, **p = 0.0027). Data represent mean ± SD. Experiment was repeated twice. c FFA release from differentiated 3T3-L1 cells cultured with Atglistatin (ATGL inhibitor) and CAY10499 (HSL inhibitor, n = 3, *p = 0.016, **p = 0.0013). Data represent mean ± SD. d FFA release from differentiated 3T3-L1 adipocytes after ApoL6 shRNA knockdown (n = 4, **p = 0.002 and 0.0019). e FFA release from human adipocytes after infection with lentiviral h-ApoL6 shRNA (n = 3, **p = 0.0016). Data represent mean ± SD. Experiment was repeated twice. f MEFs prepared from WT and ApoL6 KO E13.5 embryos were differentiated into adipocytes and infected with ApoL6-HA adenovirus. Immunoblotting with HA antibody and ApoL6 antibody (left), cell images (middle, bar = 10 μm) and FFA release (right, n = 4, **p = 0.0028, ***p < 0.001, two-way ANOVA test). Data represent mean ± SD. Independent experiments were repeated twice.